The Medicinal Chemistry Core is a newly proposed CCSG Core. The Medicinal Chemistry Core Laboratory was developed to provide the needed expertise in the area of synthesis of small molecules, modified peptides and bioconjugates for biomedical research by the Cancer Center research community. Creation of this Core was in direct response to a clearly defined need for providing synthesis of chemical reagents needed for preclinical studies (not for clinical drug development). The guiding principle was that the Center was not attempting to establish a GMP chemical production facility, but a chemical synthesis core laboratory to provide reagent grade compounds for use in validation and proof-of-principle target discovery studies. To accomplish this, there are a large number of investigators within the Center who have a need for a Medicinal Chemistry Core to provide unique reagents. These reagents are needed both for the study of the role of specific molecular targets controlling the growth and survival of cancer cells, as well as for the development of related reagents for cancer treatment. From the 2002 inception of the Medicinal Chemistry Core, its mission has been to provide very specific unique reagents to allow proof of principle and general drug discovery studies and accelerate basic sciences studies. The main purpose of the Medicinal Chemistry Core is: (1) To design and synthesize bioactive molecules in the most cost effective manner possible. (2) To optimize methods of purification of bioactive molecules at high yield. (3) To provide NMR, Mass spectrometry, and HPLC analysis for characterization of new anticancer agents. (4) To provide investigators with custom synthesis of anticancer agents in amounts ranging from milligrams to grams. (5) To provide experience and intuition for identification and optimization of lead compounds as well as promising reagents. This application requests support for a resource which continues to fulfill an essential role for peer reviewed research within the SKCCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-48
Application #
8117673
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
48
Fiscal Year
2010
Total Cost
$172,865
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Schoch, Laura K; Cooke, Kenneth R; Wagner-Johnston, Nina D et al. (2018) Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv 2:2226-2229
Cuviello, Andrea; Goyal, Anshit; Zick, Aviad et al. (2018) Sporadic Malignant Glomus Tumor of the Brachial Plexus With Response to Targeted Therapy Directed Against Oncogenic BRAF. JCO Precis Oncol 2018:
Isaacsson Velho, Pedro; Antonarakis, Emmanuel S (2018) PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol 11:475-486
Barberi, Theresa; Martin, Allison; Suresh, Rahul et al. (2018) Absence of host NF-?B p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. Cancer Immunol Immunother 67:1491-1503
Taube, Janis M; Galon, Jérôme; Sholl, Lynette M et al. (2018) Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 31:214-234
Giraldo, Nicolas A; Nguyen, Peter; Engle, Elizabeth L et al. (2018) Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. J Immunother Cancer 6:99
Boudadi, Karim; Suzman, Daniel L; Anagnostou, Valsamo et al. (2018) Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget 9:28561-28571

Showing the most recent 10 out of 2393 publications